BR112012010223A2 - purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares - Google Patents

purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares

Info

Publication number
BR112012010223A2
BR112012010223A2 BR112012010223A BR112012010223A BR112012010223A2 BR 112012010223 A2 BR112012010223 A2 BR 112012010223A2 BR 112012010223 A BR112012010223 A BR 112012010223A BR 112012010223 A BR112012010223 A BR 112012010223A BR 112012010223 A2 BR112012010223 A2 BR 112012010223A2
Authority
BR
Brazil
Prior art keywords
type
purification
staphylococcus aureus
capsular saccharides
aureus type
Prior art date
Application number
BR112012010223A
Other languages
English (en)
Portuguese (pt)
Inventor
Francesco Berti
Maria Rosaria Romano
Paolo Costantino
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43513776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012010223(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112012010223A2 publication Critical patent/BR112012010223A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112012010223A 2009-10-30 2010-11-01 purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares BR112012010223A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25690509P 2009-10-30 2009-10-30
PCT/IB2010/054934 WO2011051917A1 (en) 2009-10-30 2010-11-01 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides

Publications (1)

Publication Number Publication Date
BR112012010223A2 true BR112012010223A2 (pt) 2016-12-06

Family

ID=43513776

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012010223A BR112012010223A2 (pt) 2009-10-30 2010-11-01 purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
BR122019005883A BR122019005883A8 (pt) 2009-10-30 2010-11-01 Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019005883A BR122019005883A8 (pt) 2009-10-30 2010-11-01 Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição

Country Status (23)

Country Link
US (5) US9060965B2 (enExample)
EP (2) EP3199177A1 (enExample)
JP (4) JP5914344B2 (enExample)
CN (2) CN102971009A (enExample)
AU (1) AU2010310919B2 (enExample)
BR (2) BR112012010223A2 (enExample)
CA (1) CA2779578A1 (enExample)
CL (1) CL2012001145A1 (enExample)
CY (1) CY1118905T1 (enExample)
DK (1) DK2493498T3 (enExample)
ES (1) ES2626416T3 (enExample)
HR (1) HRP20170674T1 (enExample)
HU (1) HUE034251T2 (enExample)
LT (1) LT2493498T (enExample)
MX (2) MX2012004851A (enExample)
PL (1) PL2493498T3 (enExample)
PT (1) PT2493498T (enExample)
RS (1) RS56000B1 (enExample)
RU (1) RU2579900C2 (enExample)
SG (1) SG10201407096RA (enExample)
SI (1) SI2493498T1 (enExample)
SM (1) SMT201700275T1 (enExample)
WO (1) WO2011051917A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
JP2014507142A (ja) 2011-02-08 2014-03-27 インテグレイテッド バイオセラピューティクス，インコーポレイテッド α溶血素オリゴペプチドを含む免疫原性組成物
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
JP6435261B2 (ja) * 2012-08-31 2018-12-05 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
US20160158333A1 (en) * 2013-07-26 2016-06-09 University Of Saskatchewan Methods for producing salmonella o-antigen capsules, compositions and uses thereof
WO2016091904A1 (en) 2014-12-10 2016-06-16 Glaxosmithkline Biologicals Sa Method of treatment
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US12473379B2 (en) 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CN112986457B (zh) * 2021-02-25 2022-07-12 中国食品药品检定研究院 HPSEC-MALS法检测多糖并与Sepharose CL-4B法关联的方法
CN113234770B (zh) * 2021-06-15 2024-06-14 广州知易生物科技有限公司 脆弱拟杆菌荚膜多糖a的制备方法
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN114957509B (zh) * 2022-08-01 2022-10-21 深圳柏垠生物科技有限公司 一种可放大的可拉酸纯化方法

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2166963A (en) * 1936-11-19 1939-07-25 Sharp & Dohme Inc Antigenic polysaccharide complex
FI40107C (fi) * 1961-05-15 1968-10-10 Parke Davis & Co Menetelmä uuden stafylokokkiantigeenin valmistamiseksi
US3269913A (en) * 1962-05-11 1966-08-30 Parke Davis & Co Staphylococcal-immunizing products and methods for their production
GB995338A (en) * 1963-09-20 1965-06-16 Parke Davis & Co Polysaccharides and methods for their production
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
AU681573B2 (en) * 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6743430B1 (en) * 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
WO1996040242A1 (en) 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
CA2284606A1 (en) * 1997-03-26 1998-10-01 Brigham And Women's Hospital, Inc. Method for generating saccharide fragments
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP4472866B2 (ja) 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
DE69836977T2 (de) 1997-11-21 2007-10-18 Serono Genetics Institute S.A. Chlamydia pneumoniae genomische sequenzen und polypeptiden, fragmenten und anwendungen davon für nachweis, prevention und heilung
KR100769104B1 (ko) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
DK1093517T3 (da) 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
CA2350775A1 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
DK1163000T3 (da) 1999-03-19 2008-04-28 Glaxosmithkline Biolog Sa Vacciner imod antigener fra bakterier
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6689567B1 (en) * 1999-05-28 2004-02-10 University Of Guelph Method for assaying the function of FlaA1 and WbpM
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
ES2330083T3 (es) 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US6537577B1 (en) * 2001-06-04 2003-03-25 Bio Medical Development Corporation Method of prophylaxis for bovine mastitis
GB2379996B (en) * 2001-06-05 2004-05-19 Tayside Flow Technologies Ltd Flow means
WO2002101026A2 (en) * 2001-06-11 2002-12-19 Applied Nanosystems B.V. Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
AU2003260102A1 (en) 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
ES2504166T3 (es) 2002-09-13 2014-10-08 Novartis Vaccines And Diagnostics, Inc. Vacuna de estreptococo del grupo B
PT1565478T (pt) * 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
US7723087B2 (en) 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
JP5102487B2 (ja) 2003-03-07 2012-12-19 ワイス・ホールディングズ・コーポレイション 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体
KR101052996B1 (ko) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
ATE414535T1 (de) * 2003-06-23 2008-12-15 Baxter Int Trägerproteine für impfstoffe
WO2005009378A2 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
MXPA06000854A (es) 2003-07-24 2006-03-30 Merck & Co Inc Polipeptidos para inducir una respuesta inmune protectora en contra de staphylococcus aureus.
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
ATE460498T1 (de) * 2003-09-11 2010-03-15 Staat Der Nederlanden Vert Doo Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
AU2005214061B2 (en) 2004-02-18 2010-02-04 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
US20070172498A1 (en) 2004-02-27 2007-07-26 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
US20050250821A1 (en) * 2004-04-16 2005-11-10 Vincent Sewalt Quaternary ammonium compounds in the treatment of water and as antimicrobial wash
US7842479B2 (en) * 2004-05-21 2010-11-30 The Board Of Regents Of The University Of Nebraska Methods for altering acetic acid production and enhancing cell death in bacteria
US20070243205A1 (en) 2004-05-25 2007-10-18 Anderson Annaliesa S Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CN101023186A (zh) 2004-09-17 2007-08-22 默克公司 可诱导针对金黄色葡萄球菌的保护性免疫应答的多肽
RU2402347C2 (ru) 2004-09-22 2010-10-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
WO2006078680A2 (en) 2005-01-21 2006-07-27 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
KR101359953B1 (ko) * 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
CA2620416A1 (en) * 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics S.R.L. Zwitterionization of capsular saccharides
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
JP5286089B2 (ja) 2006-01-13 2013-09-11 バクスター・インターナショナル・インコーポレイテッド ポリサッカライドを精製する方法
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
WO2007113222A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
WO2007145689A1 (en) 2006-06-12 2007-12-21 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
GB0612854D0 (en) * 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
WO2008055501A1 (en) * 2006-11-08 2008-05-15 B-K Medical Aps Method and apparatus for two-step sterilization
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
CA2687681A1 (en) 2007-05-31 2009-03-05 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
AU2009334428B2 (en) * 2008-09-17 2014-02-20 Glaxosmithkline Biologicals S.A. Combination gas vaccines and therapeutics
AU2009302582A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
WO2010132833A1 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) * 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX373250B (es) * 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
BR112012010223A2 (pt) * 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
WO2011081075A1 (ja) * 2009-12-28 2011-07-07 キッコーマン株式会社 黄色ブドウ球菌抗原の抽出方法、黄色ブドウ球菌抗原の抽出用試薬および黄色ブドウ球菌の判定方法
US9173954B2 (en) * 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
SG186290A1 (en) * 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
KR20160085359A (ko) 2013-12-04 2016-07-15 글리코박신 아게 에스체리치아 콜라이에서 합성된 당단백질 백신에 의한 스타필로코커스 아우레우스 감염의 예방
US9775872B2 (en) 2014-08-20 2017-10-03 Professional Compounding Centers Of America Topical pharmaceutical bases for preventing viral diseases
WO2018217564A1 (en) * 2017-05-22 2018-11-29 The Children's Medical Center Corporation Combined vaccine against mycobacterium tuberculosis

Also Published As

Publication number Publication date
JP5914344B2 (ja) 2016-05-11
US20120282295A1 (en) 2012-11-08
BR122019005883A8 (pt) 2022-10-04
SI2493498T1 (sl) 2017-07-31
JP2017206564A (ja) 2017-11-24
LT2493498T (lt) 2017-05-25
US20150315225A1 (en) 2015-11-05
PT2493498T (pt) 2017-05-24
US9060965B2 (en) 2015-06-23
AU2010310919B2 (en) 2015-05-07
CN109134677A (zh) 2019-01-04
MX2012004851A (es) 2012-05-22
RU2012122237A (ru) 2013-12-10
EP2493498B1 (en) 2017-03-22
JP2016047852A (ja) 2016-04-07
MX345967B (es) 2017-02-28
EP3199177A1 (en) 2017-08-02
JP2019104940A (ja) 2019-06-27
CN102971009A (zh) 2013-03-13
ES2626416T3 (es) 2017-07-25
AU2010310919A1 (en) 2012-05-24
US20160376301A1 (en) 2016-12-29
US20190169216A1 (en) 2019-06-06
CY1118905T1 (el) 2018-01-10
EP2493498A1 (en) 2012-09-05
HUE034251T2 (en) 2018-02-28
DK2493498T3 (en) 2017-05-08
US20220089627A1 (en) 2022-03-24
RU2579900C2 (ru) 2016-04-10
US9441004B2 (en) 2016-09-13
BR122019005883A2 (enExample) 2019-09-03
RS56000B1 (sr) 2017-09-29
PL2493498T3 (pl) 2017-08-31
CA2779578A1 (en) 2011-05-05
JP2013509397A (ja) 2013-03-14
SG10201407096RA (en) 2014-12-30
WO2011051917A1 (en) 2011-05-05
CL2012001145A1 (es) 2012-09-14
US11208424B2 (en) 2021-12-28
HRP20170674T1 (hr) 2017-07-14
SMT201700275T1 (it) 2017-07-18

Similar Documents

Publication Publication Date Title
BR112012010223A2 (pt) purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
BRPI0812214A2 (pt) purificador desinfetante de efeito prolongado
SMT201600259B (it) Composizioni farmaceutiche antibatteriche
PT2453922T (pt) Composições orais antibacterianas
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI1015203A2 (pt) agentes antimicrobianos
PL2424372T3 (pl) Kompozycje przeciwdrobnoustrojowe i powiązane sposoby zastosowania
BRPI1009982A2 (pt) composição antimicrobiana hidratante
BRPI0924425A2 (pt) "combinações de substâncias ativas sinergéticas".
BR112012004781A2 (pt) diagnóstico de interferon tipo 1
PT2448582T (pt) Compostos e composições terapêuticas
BR112012012872A2 (pt) "pirrolindinas de espiroindolinona"
BRPI0809103A2 (pt) composições de magnésio e seus usos
EP2227084A4 (en) VIRUZIDE COMPOSITION
IT1395087B1 (it) Elemento ad assorbimento d'urto
BR112012002609A8 (pt) composição antimicrobiana sinergística
BRPI1007603A2 (pt) "composição de tratamento do cabelo"
BRPI0820357A2 (pt) Tratamento de purificação de materiais graxos
EP2460405A4 (en) ANTIBACTERIAL ACTIVE SUBSTANCE
BRPI0923567A2 (pt) agentes antibactericidas novos para o tratamento de infecções gram positivas
SMT201600041B (it) Agenti terapeutici 713
EP2424875A4 (en) CLEANING OF IMMUNOJUGATES
EP2461850A4 (en) DIRECTED THERAPEUTICS
EP2380876A4 (en) 1-HETERODIUM DERIVATIVE AND MEANS FOR COMBATING HARMFUL ORGANISMS
BRPI1006361A2 (pt) "artigo absorvente"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL